Title : Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.

Pub. Date : 2017 Apr 3

PMID : 28278078






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In recent years, compound BCR-ABL mutations have emerged as a new threat to CML patients by causing higher degrees of resistance involving multiple TKIs, including ponatinib. ponatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens